Sign Out
Hypoglycemia: The risk of hypoglycemia may increase with concomitant use of trelagliptin and sulfonylureas or insulin preparations. Therefore, reduction of the dosage of sulfonylureas or insulin preparations should be considered to reduce the risk of hypoglycemia when used in combination with trelagliptin.
Acute Pancreatitis: Acute pancreatitis has been associated with other DPP-4 inhibitors. After initiation of trelagliptin, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, trelagliptin should be promptly discontinued and appropriate management should be initiated.
Effects on ability to drive and use machines: The influence of trelagliptin on the ability to drive or use machine is unknown.
